{"id":"rifaximin-and-loperamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifaximin is a non-absorbed antibiotic that acts locally in the gastrointestinal tract to reduce bacterial overgrowth and associated inflammation. Loperamide is an antimotility agent that slows intestinal transit and reduces fluid secretion. Together, they address both the bacterial cause and symptom of traveler's diarrhea and irritable bowel syndrome with diarrhea (IBS-D).","oneSentence":"Rifaximin reduces pathogenic gut bacteria while loperamide decreases intestinal motility to reduce diarrhea symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:12.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Traveler's diarrhea caused by noninvasive strains of Escherichia coli"},{"name":"Irritable bowel syndrome with diarrhea (IBS-D)"}]},"trialDetails":[{"nctId":"NCT01618591","phase":"NA","title":"Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea","status":"TERMINATED","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2012-09","conditions":"Acute Watery Diarrhea, Dysentery/Febrile Diarrhea","enrollment":384},{"nctId":"NCT00292344","phase":"PHASE4","title":"Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2004-06","conditions":"Travelers' Diarrhea","enrollment":316}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifaximin and loperamide","genericName":"Rifaximin and loperamide","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin reduces pathogenic gut bacteria while loperamide decreases intestinal motility to reduce diarrhea symptoms. Used for Traveler's diarrhea caused by noninvasive strains of Escherichia coli, Irritable bowel syndrome with diarrhea (IBS-D).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}